{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:12:40Z","timestamp":1787897560022,"version":"build-2784847793"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2021,11,11]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Multidrug-resistant tuberculosis (MDR-TB) drugs have never been associated with erythrocytosis. In Eritrea, however, several cases of incident erythrocytosis had been observed in the MDR-TB hospital. This study was aimed at exploring the association between MDR-TB drugs and secondary erythrocytosis, characterising the cases, and identifying other possible risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted in Merhano National Referral MDR-TB hospital. Data were extracted from physically available clinical cards and laboratory results collected longitudinally between 23 June 2011 and 17 January 2021. Initially, univariate descriptive statistics (frequency, mean (SD), median (IQR) and range) were used as appropriate. Then, \u03c7<jats:sup>2<\/jats:sup> or Fisher \u03c7<jats:sup>2<\/jats:sup> test, and bivariate and\/or multivariate Cox proportional hazard model were used to identify the predictors of incident erythrocytosis. All statistical analyses were conducted using R, and a two-sided alpha 0.05 was used to determine the statistical significance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 257 patients\u2019 medical cards were screened, and 219 were eligible for further analysis. The median age of the patients was 38 years (range: 13\u201390 years) and 54.8% were males. During the follow-up time, 31 (14.2%) patients developed secondary erythrocytosis yielding an incidence rate of 7.8 cases per 1000 person-months. On average, the median time to onset of the event was found to be 5-months (range: 1\u201324 months). Males were more likely to develop the event than females (adjusted HR=7.13, 95% CI=1.66 to 30.53), and as body weight increases by 1 kg, the likelihood of developing secondary erythrocytosis was found to increase by 7% (adjusted HR=1.07, 95% CI=1.03 to 1.10). Moreover, all cases of secondary erythrocytosis were found to be possibly associated with the MDR-TB drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The authors hypothesised that the incident erythrocytosis is possibly be associated with MDR-TB drugs, and further studies are required to substantiate this finding.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2021-001064","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:35:24Z","timestamp":1637670924000},"page":"e001064","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Secondary erythrocytosis following drugs used in rifampicin\/multidrug-resistant tuberculosis: a retrospective cohort study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-5952","authenticated-orcid":false,"given":"Sirak","family":"Tesfamariam","sequence":"first","affiliation":[{"name":"Product Evaluation and Registration Unit, National Medicines and Food Administration, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amon Solomon","family":"Ghebrenegus","sequence":"additional","affiliation":[{"name":"Hazhaz Zonal Referral Hospital, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henok","family":"Woldu","sequence":"additional","affiliation":[{"name":"The Center for Health Analytics for National and Global Equity (C.H.A.N.G.E), Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrem","family":"Fisseha","sequence":"additional","affiliation":[{"name":"Eritrean Air-Force Military Hospital, Asmara, Eritrea"},{"name":"Merhano National Referral MDR-TB Hospital, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebremeskel","family":"Belai","sequence":"additional","affiliation":[{"name":"Merhano National Referral MDR-TB Hospital, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-5842","authenticated-orcid":false,"given":"Mulugeta","family":"Russom","sequence":"additional","affiliation":[{"name":"Eritrean Pharmacovigilance Center, National Medicines and Food Administration, Asmara, Eritrea"},{"name":"Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands"},{"name":"European Programme for Pharmacovigilance and Pharmacoepidemiology, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"2025083109465709000_8.1.e001064.1","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. World Health Organization, 2020."},{"key":"2025083109465709000_8.1.e001064.2","unstructured":"World Health Organization . Global tuberculosis report 2020, 2020."},{"key":"2025083109465709000_8.1.e001064.3","unstructured":"World Health organization TB country, regional and global profiles: Eritrea, 2020. Available: https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_&entity_type=\"country\"&lan=\"EN\"&iso2=\"ER\" [Accessed 23 Jul 2021]."},{"key":"2025083109465709000_8.1.e001064.4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5588\/ijtld.20.0558","article-title":"First molecular-based anti-TB drug resistance survey in Eritrea","volume":"25","author":"Mesfin","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025083109465709000_8.1.e001064.5","first-page":"104","article-title":"Side effects encountered in treatment of multidrug-resistant tuberculosis: a 3-year experience at first dots plus site of Chhattisgarh","volume":"3","author":"Bhardwaj","year":"2015","journal-title":"International Journal of Scientific Study"},{"key":"2025083109465709000_8.1.e001064.6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejcdt.2015.03.004","article-title":"Adverse reactions among patients being treated for multi-drug resistant tuberculosis at Abbassia chest Hospital","volume":"64","author":"Tag El Din","year":"2015","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2025083109465709000_8.1.e001064.7","doi-asserted-by":"crossref","unstructured":"Russom M et al . Nature, magnitude and risk factors of adverse drug reactions in multidrug resistant TB patients in Eritrea. Eur Respiratory Soc 2018.","DOI":"10.1183\/13993003.congress-2018.PA4746"},{"key":"2025083109465709000_8.1.e001064.8","unstructured":"Tefferi A . Diagnostic approach to the patient with polycythemia. UpToDate, 2013."},{"key":"2025083109465709000_8.1.e001064.9","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712458947"},{"key":"2025083109465709000_8.1.e001064.10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15648"},{"key":"2025083109465709000_8.1.e001064.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6667"},{"key":"2025083109465709000_8.1.e001064.12","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191587"},{"key":"2025083109465709000_8.1.e001064.13","unstructured":"Haider MZ , Anwer F . Secondary polycythemia. StatPearls, 2020."},{"key":"2025083109465709000_8.1.e001064.14","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-017-3088-5"},{"key":"2025083109465709000_8.1.e001064.15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025083109465709000_8.1.e001064.16","unstructured":"Team, R.C . R: a language and environment for statistical computing, 2013."},{"key":"2025083109465709000_8.1.e001064.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0572-7"},{"key":"2025083109465709000_8.1.e001064.18","article-title":"Hypoxemia in patients with COPD: cause, effects, and disease progression","volume":"6","author":"Kent","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083109465709000_8.1.e001064.19","unstructured":"Kanamycin summary product characteristics. Available: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/TB301part4v1.pdf"},{"key":"2025083109465709000_8.1.e001064.20","unstructured":"Capreomycin summary product characteristics. Available: http:\/\/www.ndda.kz\/upload\/dari.kz\/Vnesenie%20izmeneni\/SPC%20Capreomycin.pdf"},{"key":"2025083109465709000_8.1.e001064.21","unstructured":"Levofloxacin summary product characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/4625\/smpc#gref"},{"key":"2025083109465709000_8.1.e001064.22","unstructured":"Ethionamide summary product characteristics. Available: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/TB207part4_1.pdf"},{"key":"2025083109465709000_8.1.e001064.23","unstructured":"Cycloserine summary product characteristics. Available: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/TB236part4v1.pdf"},{"key":"2025083109465709000_8.1.e001064.24","unstructured":"Para-amino salicylic acid summary product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/granupas-epar-product-information_en.pdf"},{"key":"2025083109465709000_8.1.e001064.25","unstructured":"Pyrazinamide summary product characteristics. Available: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/TB159part4.pdf"},{"key":"2025083109465709000_8.1.e001064.26","unstructured":"Pyridoxine summary product characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/1208\/smpc#gref"},{"key":"2025083109465709000_8.1.e001064.27","unstructured":"Levothyroxine summary product characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/5682\/smpc#gref"},{"key":"2025083109465709000_8.1.e001064.28","unstructured":"Efavirez\/Emtricitabine\/Tenofovir disoproxil fumarate summary product characteristics. Available: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/HA444part4.pdf"},{"key":"2025083109465709000_8.1.e001064.29","unstructured":"Insulin Glargine summary product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/insulin-lispro-sanofi-epar-product-information_en.pdf"},{"key":"2025083109465709000_8.1.e001064.30","unstructured":"Insulin lispro summary product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lantus-epar-product-information_en.pdf"},{"key":"2025083109465709000_8.1.e001064.31","unstructured":"Metformin summary product characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/10759\/smpc#gref"},{"key":"2025083109465709000_8.1.e001064.32","unstructured":"Glibenclamide summary product characteristics. Available: https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/LicenseSPC_PA0688-040-002_07092016112043.pdf"},{"key":"2025083109465709000_8.1.e001064.33","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12256"},{"key":"2025083109465709000_8.1.e001064.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2012.02.011"},{"key":"2025083109465709000_8.1.e001064.35","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","article-title":"Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis","volume":"4","author":"Wouters","year":"2020","journal-title":"Blood Adv"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2021-001064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:47:06Z","timestamp":1756658826000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2021-001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,23]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bmjresp-2021-001064"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2021-001064","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}